Taux d'incidence des manifestations de pneumopathie interstitielle chez les patients atteints de polyarthrite rhumatoïde traités par tofacitinib

J Clin Rheumatol. 2021;27(8):e482–e490

This post hoc analysis of pooled data from 21 clinical trials in the tofacitinib clinical trial programme highlights the importance of identifying known risk factors of RA-interstitial lung disease (ILD) in clinical practice.Citera, et al. investigated incidence rates of ILD – an extra-articular manifestation of RA – in patients with RA, receiving tofacitinib 5 or 10 mg BID and sort to identify potential risk factors for ILD in these patients.

Keywords:


Publication thumbnail: Taux d'incidence des manifestations de pneumopathie interstitielle chez les patients atteints de polyarthrite rhumatoïde traités par tofacitinib
LinkedIn